QNRX (Quoin Pharmaceuticals Ltd.) חוב לטווח קצר להון

Geopolitical instability is hindering international drug trials and component procurement, slowing the progress of Quoin Pharmaceuticals (QNRX). Meanwhile, Quoin Pharmaceuticals (QNRX) is implementing software robots for data analysis and testing automated molecule screening. Production relies on a network of external contractors in Europe and the US, which mitigates logistical risks. The indicator stands at 0.00, and this price chart, serving as the primary valuation tool, visualizes the dynamics of this business.

For Quoin Pharmaceuticals (QNRX), a developer of monopoly drugs for rare dermatoses with minimal synthesis costs, the structure of short-term liabilities relative to capital is critical, which, through the current value of 0.00, correlates loans with maturities of up to one year with equity, allowing the investor to assess liquidity risk and the balance between financial stability and the efficient use of leverage.